| Patient | Lorraine Hansberry |
|---|---|
| Date of birth | 1993-05-19 |
| Identifiers | MRN HR-ML034-SYN; SSN (made up) 000-34-7158 |
| Document date | 2026-10-05 |
| Author | Odette Marchetti-Fields, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Review six weeks after pancreaticoduodenectomy: pathology, diabetes, digestion, and the plan for chemotherapy after surgery. [S]
Ms. Hansberry returns six weeks after a pylorus-preserving pancreaticoduodenectomy with resection of a segment of the superior mesenteric vein. She was in hospital nine days; her stomach was slow to empty for the first week and then recovered. Insulin glargine was started four days after surgery when her glucose rose, and her home fasting readings are now 140 to 170 mg/dL on 8 units. She finished four weeks of enoxaparin two weeks ago. Since surgery her stools have been loose and pale after larger meals despite pancrelipase. She has lost 2.4 kg since surgery. Pain is 2 out of 10 at the wound and she rarely needs oxycodone. She is writing again for an hour each morning. Fingertip tingling is barely there. She saw Dr. Adeyemi-Rourke last week, who recommends chemotherapy after surgery starting next week. She has had no thoughts of self-harm. [S]
| Element | Detail |
|---|---|
| Operation | Pylorus-preserving pancreaticoduodenectomy with vein resection; nine days in hospital; delayed gastric emptying resolved |
| Pathology | ypT2N1: 2.3 cm residual adenocarcinoma, 2 of 18 nodes, perineural invasion; all margins clear (R0); partial treatment response |
| Diabetes | Insulin glargine 8 units since day 4; fasting 140 to 170 mg/dL |
| Digestion | Loose, pale stools after larger meals; weight down 2.4 kg since surgery |
| Plan proposed | Six cycles of fluorouracil, leucovorin and irinotecan, without oxaliplatin, starting next week |
| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Tired in the afternoons; weight 51.8 kg; no fever |
| Gastrointestinal | Positive | Loose, pale stools after larger meals; eating five small meals; no vomiting |
| Endocrine | Positive | Fasting glucose 140 to 170 mg/dL; no low readings |
| Neurological | Negative | Fingertip tingling barely present |
| Cardiovascular | Negative | No leg swelling or calf pain |
| Psychiatric | Positive | Relieved about the margins, worried about the lymph nodes; PHQ-9 7, GAD-7 6; no thoughts of self-harm |
6 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Pantoprazole 40 mg delayed-release oral tablet, one tablet by mouth once daily before breakfast | One tablet daily before breakfast | Oral route | 2026-04-20 | active | S |
| Ferric carboxymaltose 50 mg/mL injection, 750 mg intravenously, two doses one week apart | 750 mg intravenously; two doses one week apart | Intravenous route | 2026-04-24 to 2026-05-01 | completed | S |
| Oxycodone 5 mg oral tablet, one tablet by mouth every 4 hours as needed for pain | One tablet every 4 hours as needed | Oral route | 2026-05-04 | active | S |
| Senna 8.6 mg oral tablet, two tablets by mouth at night while taking oxycodone | Two tablets at night | Oral route | 2026-05-04 | active | S |
| Pancrelipase delayed-release capsule (lipase 36,000 units), two capsules with each meal and one with each snack | Two capsules with each meal, one with each snack | Oral route | 2026-05-04 to 2026-10-05 | completed | S |
| Oxaliplatin 5 mg/mL injection, 135 mg (85 mg/m2) intravenously over 2 hours on day 1 of each 14-day cycle, for six cycles | Day 1 every 14 days for six cycles | Intravenous route | 2026-05-18 to 2026-07-27 | completed | S |
| Irinotecan 20 mg/mL injection, 238 mg (150 mg/m2) intravenously over 90 minutes on day 1 of each 14-day cycle, cycles 1 to 5 | Day 1 every 14 days, cycles 1 to 5 | Intravenous route | 2026-05-18 to 2026-07-13 | completed | S |
| Irinotecan 20 mg/mL injection, 190 mg (120 mg/m2, one dose level lower) intravenously on day 1 of cycle 6 | Day 1 of cycle 6 | Intravenous route | 2026-07-27 to 2026-07-27 | completed | S |
| Leucovorin 10 mg/mL injection, 634 mg (400 mg/m2) intravenously over 2 hours on day 1 of each 14-day cycle, for six cycles | Day 1 every 14 days for six cycles | Intravenous route | 2026-05-18 to 2026-07-27 | completed | S |
| Fluorouracil 50 mg/mL injection, 3800 mg (2400 mg/m2) by continuous infusion over 46 hours through the port from day 1 of each 14-day cycle, for six cycles, with no bolus | 46-hour infusion from day 1 every 14 days for six cycles | Intravenous route | 2026-05-18 to 2026-07-29 | completed | S |
| Pegfilgrastim 6 mg/0.6 mL prefilled syringe, 6 mg under the skin on day 3 of each cycle, after the pump is disconnected | 6 mg on day 3 of each cycle | Subcutaneous route | 2026-05-20 to 2026-07-29 | completed | S |
| Ondansetron 8 mg oral tablet, one tablet by mouth every 8 hours as needed for nausea | One tablet every 8 hours as needed | Oral route | 2026-05-18 | active | S |
| Olanzapine 5 mg oral tablet, one tablet by mouth at night on days 1 to 4 of each cycle | One tablet at night on days 1 to 4 | Oral route | 2026-05-18 | active | S |
| Loperamide 2 mg oral capsule, two capsules at the first loose stool, then one after each loose stool, no more than eight a day unless directed | 4 mg at onset, then 2 mg after each loose stool | Oral route | 2026-05-18 | active | S |
| Apixaban 2.5 mg oral tablet, one tablet by mouth twice daily during chemotherapy, stopped three days before surgery | One tablet twice daily | Oral route | 2026-06-29 to 2026-08-21 | completed | S |
| Potassium chloride 20 mEq extended-release tablet, two tablets by mouth today, then one tablet daily for three days | 40 mEq today, then 20 mEq daily for three days | Oral route | 2026-07-16 to 2026-07-19 | completed | S |
| Enoxaparin 40 mg/0.4 mL prefilled syringe, 40 mg under the skin once daily for 28 days after surgery | 40 mg once daily for 28 days | Subcutaneous route | 2026-08-24 to 2026-09-21 | completed | S |
| Insulin glargine 100 units/mL pen, 8 units under the skin at night | 8 units at night | Subcutaneous route | 2026-08-28 to 2026-10-05 | completed | S |
| Insulin glargine 100 units/mL pen, 10 units under the skin at night | 10 units at night | Subcutaneous route | 2026-10-05 | active | S |
| Pancrelipase delayed-release capsule (lipase 36,000 units), three capsules with each meal and two with each snack | Three capsules with each meal, two with each snack | Oral route | 2026-10-05 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-10-05 | Body height | 163 | cm | S |
| 2026-10-05 | Body weight | 51.8 | kg | S |
| 2026-10-05 | Body mass index (BMI) [Ratio] | 19.5 | kg/m2 | S |
| 2026-10-05 | Systolic blood pressure | 106 | mm[Hg] | S |
| 2026-10-05 | Diastolic blood pressure | 68 | mm[Hg] | S |
| 2026-10-05 | Heart rate | 86 | /min | S |
| 2026-10-05 | Respiratory rate | 16 | /min | S |
| 2026-10-05 | Body temperature | 36.7 | Cel | S |
| 2026-10-05 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-10-05 | Hemoglobin [Mass/volume] in Blood | 10.6 | g/dL | 12-15.5 g/dL | Low | S |
| 2026-10-05 | Leukocytes [#/volume] in Blood by Automated count | 8.2 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 2026-10-05 | Neutrophils [#/volume] in Blood by Automated count | 5.1 | 10*3/uL | 1.5-7.7 10*3/uL | Normal | S |
| 2026-10-05 | Platelets [#/volume] in Blood by Automated count | 302 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 2026-10-05 | Sodium [Moles/volume] in Serum or Plasma | 137 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-10-05 | Potassium [Moles/volume] in Serum or Plasma | 4.3 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-10-05 | Creatinine [Mass/volume] in Serum or Plasma | 0.71 | mg/dL | 0.59-1.04 mg/dL | Normal | S |
| 2026-10-05 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 116 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-10-05 | Glucose [Mass/volume] in Serum or Plasma | 156 | mg/dL | 70-99 mg/dL | High | S |
| 2026-10-05 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 22 | U/L | 7-35 U/L | Normal | S |
| 2026-10-05 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 24 | U/L | 8-35 U/L | Normal | S |
| 2026-10-05 | Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma | 110 | U/L | 35-104 U/L | High | S |
| 2026-10-05 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.5 | mg/dL | 0.1-1.2 mg/dL | Normal | S |
| 2026-10-05 | Albumin [Mass/volume] in Serum or Plasma | 3.4 | g/dL | 3.5-5 g/dL | Low | S |
| 2026-10-05 | Cancer Ag 19-9 [Units/volume] in Serum or Plasma | 18 | U/mL | <=35 U/mL | Normal | S |
| 2026-10-05 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 7 | {score} | S | ||
| 2026-10-05 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 6 | {score} | S | ||
| 2026-10-05 | Pain severity - 0-10 verbal numeric rating [Score] - Reported | 2 | {score} | S | ||
| 2026-10-05 | Albumin/Creatinine [Mass Ratio] in Urine | 12 | mg/g | <=30 mg/g | Normal | S |
Vital signs recorded on 2026-10-05; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Thin, well; weight 51.8 kg; blood pressure 106/68, pulse 86 |
| Abdomen | Healed upper midline and right subcostal incision without hernia or redness; soft; mildly tender at the wound |
| Eyes | No icterus |
| Feet | Monofilament sensation and pulses normal; no lesions |
| Extremities | No leg swelling |
| Psychiatric | Engaged; planning her writing around the treatment days |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Epigastric pain for about two months, boring through to the back and worse after meals and lying flat, with nausea, early fullness, a loss of 5 kg (8 percent of her weight), and pale, loose stools: an upper abdominal cause such as a bleeding ulcer or a pancreatic or duodenal tumor must be found. Upper endoscopy and pancreas-protocol CT booked this week | resolved | confirmed | R10.13 | S — Synthetic presenting problem anchored to the documented collapse in pain and the account of a suspected duodenal ulcer. Superseded by the diagnosis at the second visit. |
| Iron deficiency anemia from chronic upper gastrointestinal blood loss: black stools on and off for three weeks, two near-fainting spells, hemoglobin 9.1 g/dL, MCV 74 fL, ferritin 6 ng/mL | active | confirmed | D50.0 | S — Synthetic finding anchored to the documented account that she was told she had anemia and bleeding ulcers. |
| New hyperglycemia: A1c 6.6% and random glucose 132 mg/dL in a lean woman of 32 who is losing weight; new diabetes with weight loss can be the first sign of a pancreatic cancer, so it is to be confirmed and explained, not labeled type 2 | resolved | confirmed | R73.09 | S — Synthetic finding; superseded when diabetes due to the pancreatic cancer was recorded at the second visit. |
| Adenocarcinoma of the head of the pancreas, 3.1 cm, invading the duodenum, borderline resectable (tumor contact of more than half the circumference of the superior mesenteric vein, no arterial contact), no distant spread, CA 19-9 486 U/mL after biliary drainage; on EUS-guided biopsy; synthetic modern detail linked to her documented cancer, whose primary site the sources record differently | active | confirmed | C25.0 | S — Synthetic histology, site, stage and course; the sources say she died of cancer and differ on whether it was pancreatic, duodenal, or colonic with spread to the pancreas (R). See sources.md. |
| Diabetes due to the pancreatic cancer (pancreatogenic, type 3c): A1c 6.6% at intake and fasting glucose 141 mg/dL | active | confirmed | E08.9 | S — Synthetic consequence of the synthetic tumor. |
| Exocrine pancreatic insufficiency from obstruction of the pancreatic duct: pale, floating, loose stools after fatty meals and weight loss | active | confirmed | K86.81 | S — Synthetic consequence of the synthetic tumor; diagnosed clinically, as guidance allows in pancreatic cancer. |
| Cancer-related pain in the upper abdomen and back, 6 out of 10, with sleep broken by it | active | confirmed | G89.3 | S — Synthetic symptom of the synthetic tumor. |
| Obstruction of the distal common bile duct by the tumor, relieved by a covered metal stent placed at ERCP | resolved | confirmed | K83.1 | S — Synthetic consequence of the synthetic tumor. |
| Chemotherapy-induced diarrhea from irinotecan, grade 2 (five to six watery stools a day above her usual), starting on day 3 of cycle 5, with low potassium and magnesium and mild dehydration; no fever, blood or neutropenia; resolved | resolved | confirmed | K52.1 | S — Synthetic treatment effect; not a historical claim. |
| Oxaliplatin peripheral neuropathy, grade 1: tingling in the fingers and toes in the cold, lasting a few days after each cycle, with mild tingling at the fingertips between cycles; no effect on writing or buttons | active | confirmed | G62.0 | S — Synthetic common effect of oxaliplatin. |
| After pylorus-preserving pancreaticoduodenectomy with superior mesenteric vein resection: loss of the head of the pancreas, with more marked exocrine insufficiency and insulin-requiring diabetes | active | confirmed | Z90.411 | S — Synthetic consequence of the synthetic operation. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Surgical pathology | After resection | Up to date | ypT2N1 (2 of 18 nodes), R0, perineural invasion, CAP tumor regression score 2 |
| Laboratory | CA 19-9 | At diagnosis after biliary drainage, every two cycles during treatment, before surgery, after surgery, then every three to six months | Completed today | 18 U/mL, normal |
| Laboratory | Blood count with neutrophils and platelets | Before chemotherapy after surgery | Completed today | Hemoglobin 10.6 g/dL, white cells 8.2, neutrophils 5.1, platelets 302 |
| Laboratory | Kidney and liver function, electrolytes and albumin | Before chemotherapy after surgery | Completed today | Sodium 137, potassium 4.3 mmol/L; creatinine 0.71 mg/dL, eGFR 116; ALT 22, AST 24, alkaline phosphatase 110 U/L, bilirubin 0.5 mg/dL; albumin 3.4 g/dL |
| Imaging | Baseline CT after surgery | Before chemotherapy after surgery or within three months of surgery | Due | Ordered with the oncology team for before the third cycle after surgery; the CT before surgery showed no spread |
| Medication safety | Venous thromboembolism prophylaxis | After surgery and during chemotherapy | Completed today | Enoxaparin for four weeks after surgery completed; apixaban 2.5 mg twice daily to restart with chemotherapy |
| Self-management | Weight, nutrition and enzyme replacement | Each visit | Completed today | Weight 51.8 kg, 6.5 percent below the weight at diagnosis; pancrelipase increased; dietitian this week |
| Laboratory | Glucose and home readings | Each visit and before each cycle | Completed today | Glucose 156 mg/dL; home fasting 140 to 170 on 8 units of glargine |
| Laboratory | A1c | Every three months while treatment changes | Up to date | 7.0% eight weeks ago; next in December, three months after that one |
| Examination | Dilated eye examination and urine albumin-to-creatinine ratio | At diagnosis of diabetes, then yearly | Completed today | Urine albumin-to-creatinine ratio 12 mg/g today, normal, closing part of the deviation recorded at cycle 4. The dilated eye examination is booked for next week |
| Examination | Foot examination | At diagnosis of diabetes, then yearly | Completed today | Normal sensation and pulses |
| Examination | Oxaliplatin neuropathy: symptoms and examination | At each visit after oxaliplatin | Completed today | Almost resolved |
| Survey | Pain score and opioid review | Each visit | Completed today | Pain 2 out of 10 at the wound |
| Survey | Distress and depression screen (PHQ-9, GAD-7) | At diagnosis, at each treatment phase, and when symptoms change | Completed today | PHQ-9 7 and GAD-7 6 |
| Self-management | Serious illness conversation and advance care planning | At diagnosis and at each change in treatment | Completed today | Reviewed with palliative care last week; to be recorded formally at the preventive visit |
Goal progress:
Guideline basis: NCCN Clinical Practice Guidelines in Oncology: Pancreatic Adenocarcinoma (2026); Khorana AA, et al. Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2016;34(21):2541-2556 (PMID 27247221) (2016); Khorana AA, et al. Potentially Curable Pancreatic Adenocarcinoma: ASCO Clinical Practice Guideline Update. J Clin Oncol 2019;37(23):2082-2088 (PMID 31180816) (2019); Sanders JJ, et al. Palliative Care for Patients With Cancer: ASCO Guideline Update. J Clin Oncol 2024;42(19):2336-2357 (PMID 38748941) (2024); Key NS, et al. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Guideline Update. J Clin Oncol 2023;41(16):3063-3071 (PMID 37075273) (2023); American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes-2026 (classification of diabetes, including diabetes of the exocrine pancreas) (2026); CMID: Clinical Monitoring Intelligence Database, diabetes mellitus (type 2) and anemia monographs (2026); Depression and Suicide Risk in Adults: Screening (2023)
Follow-up: Chemotherapy after surgery from next week. Dietitian and eye examination this week and next. Preventive visit in about two weeks. Call for fever of 38.0 °C or more, yellow eyes, low glucose readings, or worsening diarrhea. Next scheduled visit 2026-10-21: periodic adult preventive visit during chemotherapy after surgery. [S]